What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to officially report Amgen's unaudited financial results for the third quarter and the first nine months of 2013, as well as its financial position as of September 30, 2013. It serves to attach the press release containing these results and important details about the company's non-GAAP financial reporting.

What are some of the significant adjustments Amgen makes to its GAAP results when reporting non-GAAP measures?

Significant adjustments include the impact of expensing stock options, non-cash amortization of product technology rights and intangible assets acquired in business combinations, acquisition-related expenses (such as transaction and bridge financing costs for the Onyx deal), costs associated with cost-saving initiatives, legal expenses, and non-cash interest expense on convertible notes. The company also adjusts for the tax effects of these items.

What is Free Cash Flow (FCF) as defined by Amgen in this filing?

Amgen defines Free Cash Flow (FCF) as a non-GAAP measure computed by subtracting capital expenditures from cash flow from operations, both as determined in accordance with GAAP. The company believes FCF provides an additional measure of its liquidity.

AMGN 8-K: Earnings & Results

Q: Why does Amgen provide non-GAAP financial measures?

Amgen uses non-GAAP financial measures to provide supplementary information that it believes facilitates additional analysis by investors. The company aims to exclude certain items such as stock option expenses, acquisition-related costs (including amortization of intangibles), cost-saving initiatives, and legal expenses to offer a more comparable view of its ongoing operational performance and profitability, both before and after these items are incurred.

Summary

Amgen Inc. (AMGN) filed an 8-K on October 22, 2013, reporting its unaudited financial results for the third quarter and the first nine months of 2013. The filing primarily serves to attach a press release detailing these results and providing reconciliations for non-GAAP financial measures. Investors should note the company's emphasis on adjusted metrics, which exclude various items like stock option expenses, acquisition-related costs (including amortization of intangibles and transaction/financing costs related to the Onyx acquisition), cost-saving initiatives, legal expenses, and non-cash interest expense. The company provided detailed explanations for its adjustments to GAAP measures, aiming to offer a more comparable view of operational performance by excluding one-time or non-cash charges. Amgen also highlighted its use of Free Cash Flow (FCF) as a non-GAAP measure of liquidity, calculated as cash flow from operations minus capital expenditures. This filing is crucial for understanding the company's reported performance beyond standard GAAP, offering insights into its operational efficiency and financial health as presented by management.

Key Highlights

1Amgen announced its Q3 and year-to-date 2013 financial results via an 8-K filing on October 22, 2013.
2The report includes a press release with unaudited financial results and financial position as of September 30, 2013.
3The company provided significant detail on its non-GAAP financial measures, explaining adjustments made to GAAP results.
4Key adjustments to GAAP include expensing of stock options, amortization of acquired intangible assets, acquisition-related expenses (including Onyx deal costs), cost-saving initiatives, legal expenses, and non-cash interest.
5Amgen also reported Free Cash Flow (FCF) as a non-GAAP liquidity measure.
6The filing indicates the completion of the Onyx business combination, with associated transaction and bridge financing costs being adjusted for.
7Reconciliations for non-GAAP to GAAP measures are provided within the attached press release (Exhibit 99.1).

AMGEN INC 8-K Report, Financial Results (Oct 22, 2013)

Summary

Key Highlights

Frequently Asked Questions